Julieta Trinks

Dr. Julieta Trinks

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2016 in Expert Opinion on Drug Metabolism & Toxicology
Verified
Journal Article
Closed access
IEIsabella Esposito
Isabella Esposito
JTJulieta Trinks
Julieta Trinks
VSVicente Soriano
Vicente Soriano
Introduction: The treatment of hepatitis C virus (HCV) infection has dramatically improved in recent years with the widespread use of interferon-free combination regimens. Despite the high sustained virological response (SVR) rates (over 90%) obtained with direct-acting antivirals (DAAs), drug resistance has emerged as a potential challenge. The high replication rate of HCV and the low fidelity of its RNA polymerase result in a high degree of genetic variability in the HCV population, which ultimately explains the rapid selection of drug resistance associated variants (RAVs). Areas covered: Results from clinical trials and real-world experience have both provided important information on the rate and clinical significance of RAVs. They can be present in treatment-naive patients as natural polymorphisms although more frequently they are selected upon treatment failure. In patients engaged in high-risk behaviors, RAVs can be transmitted. Expert opinion: Although DAA failures generally occur in less than 10% of treated chronic hepatitis C patients, selection of drug resistance is the rule in most cases. HCV re-treatment options are available, but first-line therapeutic strategies should be optimized to efficiently prevent DAA failure due to baseline HCV resistance. Considerable progress is being made and next-generation DAAs are coming with pangenotypic activity and higher resistance barrier.

29 July 2015 in BMC Genomic Data
Verified
Journal Article
Open access
PDF file
APAna Cecilia Pontoriero
Ana Cecilia Pontoriero
JTJulieta Trinks
Julieta Trinks
MHMaría Laura Hulaniuk
María Laura Hulaniuk
MCMariela Caputo
Mariela Caputo
LFLisandro Fortuny
Lisandro Fortuny
DFDiego Flichman
Diego Flichman
The global burden of chronic liver disease is rising. Besides environmental, behavioral, viral and metabolic factors, genetic polymorphisms in patatin-like phospholipase-3 (PNPLA3) and vitamin D receptor (VDR) genes have been related to the development of chronic liver disease and progression towards liver cancer. Although their prevalence differs remarkably among ethnic groups, the frequency of these polymorphisms in South American populations -whose genetic background is highly admixed- has been poorly studied. Hence, the aim of this study was to characterize polymorphisms related to chronic liver disease and their association with the genetic ancestry of South American populations. DNA samples from 258 healthy unrelated male volunteers were analyzed. The frequencies of G and C alleles of rs738409 polymorphism (PNPLA3 gene) were 74 % and 26 %, respectively; whereas the bAt (CCA) haplotype (VDR gene) was observed in 32.5 % of the samples. The GG genotype of PNPLA3 rs738409 and the bAt (CCA) haplotype -associated with an increased risk of chronic liver disease and progression towards liver cancer- were significantly more frequent among samples exhibiting maternal and paternal Native American haplogroups (63.7 % and 64.6 %), intermediate among admixed samples (45.1 % and 44.9 %; p = 0.03) and the lowest for Non-native American ancestry (30.1 % and 29.6 %; p = 0.001 and p = 0.0008). These results suggest that individuals with Native American ancestry might have a high risk of chronic liver disorders and cancer. Furthermore, these data not only support the molecular evaluation of ancestry in multi-ethnic population studies, but also suggest that the characterization of these variants in South American populations may be useful for establishing public health policies aimed at high risk ethnic communities.

7 March 2017 in Liver International
Verified
Journal Article
Closed access
PDF file
JTJulieta Trinks
Julieta Trinks
NNNao Nishida
Nao Nishida
MHMaría Laura Hulaniuk
María Laura Hulaniuk
MCMariela Caputo
Mariela Caputo
TTTakayo Tsuchiura
Takayo Tsuchiura
MMMasashi Mizokami
Masashi Mizokami

16 June 2021 in Metabolomics
Verified
Journal Article
Closed access
PDF file
FMFlavia Noelia Mazzini
Flavia Noelia Mazzini
FCFrank Cook
Frank Cook
JGJohn Gounarides
John Gounarides
SMSebastián Marciano
Sebastián Marciano
LHLeila Haddad
Leila Haddad
JTJulieta Trinks
Julieta Trinks

20 May 2014 in The Pharmacogenomics Journal
Verified
Journal Article
Closed access
PDF file
JTJulieta Trinks
Julieta Trinks
MHM L Hulaniuk
M L Hulaniuk
MCM Caputo
M Caputo
LPL Burgos Pratx
L Burgos Pratx
VRV Ré
V Ré
DFD Flichman
D Flichman

21 December 2018 in Viruses
Verified
Journal Article
Open access
PDF file
IEIsabella Esposito
Isabella Esposito
SMSebastián Marciano
Sebastián Marciano
LHLeila Haddad
Leila Haddad
OGOmar Galdame
Omar Galdame
AFAlejandra Franco
Alejandra Franco
JTJulieta Trinks
Julieta Trinks
This study aimed to assess the prevalence of natural resistance-associated substitutions (RASs) to NS3, NS5A and NS5B inhibitors in 86 genotype 1 Hepatitis C Virus (HCV)-infected patients from Buenos Aires, Argentina, and to determine their effect on therapy outcome. Additionally, virological, clinical and host genetic factors were explored as predictors of the presence of baseline RASs. NS3 RASs (39.2%) were more prevalent than NS5A RASs (25%) and NS5B RASs (8.9%). In the three regions, the frequencies of RASs were significantly higher in HCV-1b than in HCV-1a. The prevalence of Y93H, L159F and Q80K were 1.3%, 6.3% and 2.5%, respectively. IFNL3 CC genotype was identified as an independent predictor of the presence of baseline RASs in NS5A and NS3 genes (p = 0.0005 and p = 0.01, respectively). Sustained virologic response was achieved by 93.3% of the patients after receiving direct-acting antivirals (DAAs), although 48.7% of them showed baseline RASs related to the DAA-regimen. Notably, the prevalence of clinically relevant RASs in the three genes was lower than that observed around the world. The baseline presence of RASs in both subtypes did not appear to affect therapy outcome. These results support the need to evaluate resistance patterns in each particular country since RASs´ prevalence significantly vary worldwide.